Home | Biogen
Biogen doubles up on deals for small molecules
Biogen Lifts Profit Estimates as Investors Look to Alzheimer's Drug | Barron's
Biogen Plunges After Making Changes to Alzheimer's Drug Trial | BioSpace
Biogen Foundation | Biogen
Biogen Recoups Much-Needed $2.3B with Sale of Samsung Bioepis Stake | BioSpace
Biogen and Alcyone Therapeutics partner up for novel device for neurological ASO therapies
Biogen - Биоген - Photos | Facebook
Biogen bags Karyopharm neurological drug in $217M deal | Fierce Biotech
Biogen-C | Rachael Rosewood Skin Clinic
Biogen begins cutting jobs following disastrous debut of its Alzheimer's drug - The Boston Globe
Biogen shakes up R&D role, splitting it into two
Broad scales up as Biogen scales back in Kendall Square - The Boston Globe
Company | Biogen
Biogen Foundation | Biogen
Biogen's stock rises 3% after releasing new data on late-stage Alzheimer's drug
Biogen - Биоген - Photos | Facebook
Drug companies are making an accounting change after the SEC cracked down on Biogen - MarketWatch
Under-pressure Biogen aims to please restive investors with bigger, better board | Fierce Pharma
Biogen Stock Flies On Upgrade; Why Alzheimer's Is A $7 Billion Opportunity | Investor's Business Daily
Biogen teams up with Ginkgo Bioworks in gene therapy manufacturing pact - MedCity News
Biogen - Wikipedia
Biogen shares soar after patent victory | Financial Times
Biogen, at a Crossroads, Surges on Promising Alzheimer's Drug Assessment - WSJ
